FDA Approves Precigen's Immunotherapy for Rare Respiratory Tumors and RRP
The FDA has approved Papzimeos, a novel immunotherapy for adult recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV 6 or 11, offering a potential alternative to repeated surgeries with durable responses observed in clinical trials.